Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | DPP9 | Q86TI2 | 9/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MDH1 | P40925 | 1/20 | 0.35 |
| ▸ | MDH2 | P40926 | 1/20 | 0.35 |
| ▸ | GLMN | Q92990 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8294972 | 0.87 | MEN1 (0.49) | MEN1MAPK1KMT2ADPP9DPP8 | |
| SCHEMBL16259930 | 0.84 | MEN1 (0.52) | MEN1MAPK1KMT2ADPP9DPP8 | |
| SCHEMBL30680713 | 0.83 | MEN1 (0.37) | MEN1MAPK1KMT2ADPP9DPP8 | |
| SCHEMBL16540347 | 0.82 | MEN1 (0.50) | MEN1MAPK1KMT2ADPP9DPP8 | |
| SCHEMBL30684977 | 0.81 | MEN1 (0.49) | MEN1MAPK1KMT2ADPP9DPP8 | |
| SCHEMBL18776035 | 0.80 | DPP9 (0.45) | MEN1MAPK1KMT2ADPP9DPP8 | |
| SCHEMBL18785743 | 0.80 | MEN1 (0.43) | MEN1MAPK1KMT2ADPP9DPP8 | |
| SCHEMBL27641283 | 0.78 | EPHX2 (0.43) | MEN1KMT2ADPP9DPP8EPHX2 | |
| SCHEMBL13287421 | 0.78 | MEN1 (0.55) | MEN1MAPK1KMT2ADPP9DPP8 | |
| SCHEMBL25736732 | 0.78 | DPP9 (0.47) | MEN1MAPK1KMT2ADPP9DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353833-A1 | DPP9 BINDING COMPOUNDS | UNIV ANTWERPEN (BE) | 2025-11-20 | — | — | US | disclosed |
| WO-2023233024-A1 | DPP9 BINDING COMPOUNDS | UNIVERSITEIT ANTWERPEN (BE) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023233024-A1 | DPP9 BINDING COMPOUNDS | UNIVERSITEIT ANTWERPEN (BE) | 2023-12-07 | — | — | WO | disclosed |
| US-20100160328-A1 | NEW COMPOUNDS USEFUL FOR DPP-IV ENZYME INHIBITION | SANOFI-AVENTIS (FR) | 2010-06-24 | — | — | US | disclosed |
| US-20100160328-A1 | NEW COMPOUNDS USEFUL FOR DPP-IV ENZYME INHIBITION | SANOFI-AVENTIS (FR) | 2010-06-24 | — | — | US | disclosed |
| US-20100160328-A1 | NEW COMPOUNDS USEFUL FOR DPP-IV ENZYME INHIBITION | SANOFI-AVENTIS (FR) | 2010-06-24 | — | — | US | disclosed |
| US-7652021-B2 | (2S)-4,4-difluoro-1-{N-[3-(pyrimidin-2-ylamino)-1-adamantyl]glycyl}pyrrolidine-2-carbonitrile; dipeptidyl peptidase IV enzyme inhibitors; non-insulin dependent diabetes mellitus | SANOFI-AVENTIS (FR) | 2010-01-26 | — | — | US | disclosed |
| US-7652021-B2 | (2S)-4,4-difluoro-1-{N-[3-(pyrimidin-2-ylamino)-1-adamantyl]glycyl}pyrrolidine-2-carbonitrile; dipeptidyl peptidase IV enzyme inhibitors; non-insulin dependent diabetes mellitus | SANOFI-AVENTIS (FR) | 2010-01-26 | — | — | US | disclosed |
| US-7652021-B2 | (2S)-4,4-difluoro-1-{N-[3-(pyrimidin-2-ylamino)-1-adamantyl]glycyl}pyrrolidine-2-carbonitrile; dipeptidyl peptidase IV enzyme inhibitors; non-insulin dependent diabetes mellitus | SANOFI-AVENTIS (FR) | 2010-01-26 | — | — | US | disclosed |
| EP-1664031-B1 | ADAMANTANE AND AZABICYCLO-OCTANE AND NONANE DERIVATIVES PROCESS OF THEIR PREPARATION AND THEIR USE AS DPP-IV INHIBITORS | SANOFI AVENTIS (FR) | 2007-12-19 | — | — | EP | disclosed |
| US-20060276487-A1 | New compounds useful for DPP-IV enzyme inhibition | SANOFI-AVENTIS (FR) | 2006-12-07 | — | — | US | disclosed |
| EP-1664031-A2 | ADAMANTANE AND AZABICYCLO-OCTANE AND NONANE DERIVATIVES PROCESS OF THEIR PREPARATION AND THEIR USE AS DPP-IV INHIBITORS | Sanofi-Aventis (FR) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005021536-A2 | ADAMANTANE AND AZABICYCLO-OCTANE AND NONANE DERIVATIVES, PROCESS OF THEIR PREPARATION AND THEIR USE AS DPP-IV INHIBITORS | SANOFI-AVENTIS (FR) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353833-A1 | DPP9 BINDING COMPOUNDS | DPP9, DPP7, DPP3 | MEN1 3346/4885MAPK1 2779/4885KMT2A 3448/4885 |
| US-20060276487-A1 | New compounds useful for DPP-IV enzyme inhibition | DPP4, DPP7, DPP9 | MEN1 3952/4885MAPK1 3403/4885KMT2A 4096/4885 |
| US-20100160328-A1 | NEW COMPOUNDS USEFUL FOR DPP-IV ENZYME INHIBITION | DPP4, DPP7, DPP9 | MEN1 3952/4885MAPK1 3403/4885KMT2A 4096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.